CSPC INNOVATION PHARMACEUTICAL CO.,LTD
Commitment to healthy life, faith in goodness
CSPC Innovation Pharmaceutical Co., Ltd. is a subsidiary of CSPC Pharmaceutical Group, a constituent stock of the Hang Seng Index in Hong Kong. It has developed into an innovative company integrating biopharmaceuticals, active pharmaceutical ingredients (APIs), and functional foods. Upholding the corporate philosophy of “Commitment to Healthy Life, Faith to Goodness”, CSPC Innovation insists on leading product development through technological innovation, strictly adheres to product quality with a benevolent mindset, and advances courageously in promoting public nutritional health and contributing to the building of a healthy China.-
-
3Three major product segments
-
-
-
-
470 +Over 470 patent applications
-
-
-
-
2300 +More than 2,300 employees
-
-
-
-
70Marketing in nearly 70 countries or regions
-
-
-
-
22 major innovative drug R&D platforms
-
-
-
-
1515 pipelines under development
-
-
Company News
-
-
-
2026/ 08/13
CSPC Innovation’s Subsidiary Receives Upfront Payment under the Cooperation, Option and Licence Agreement with AstraZeneca
Announcement of CSPC Innovation Pharmaceutical Co., Ltd. on the Receipt of Upfront Payment under the Cooperation, Option and Licence Agreement Signed with AstraZeneca by its Holding Subsidiary
-
-
-
-
2026/ 08/04
CSPC Innovation’s SYS6090 Initiates Phase Ib/II Clinical Trial
On August 3, CSPC Innovation Pharmaceutical Co., Ltd. (Stock Code: 300765.SZ) announced that its holding subsidiary CSPC Giant Stone Biopharmaceutical Co., Ltd. (hereinafter referred to as “Giant Stone Bio”) has recently initiated a Phase Ib/II clinical trial (SYS6090‑008) to evaluate the safety, tolerability and efficacy of combination therapy with SYS6090 Injection in participants with advanced or metastatic colorectal cancer.
-
-
-
-
2026/ 06/27
CSPC Innovation Initiates Phase III Clinical Trial of SYS6010
On June 26, CSPC Innovation Pharmaceutical Co., Ltd. (stock code: 300765.SZ) released an announcement stating that its holding subsidiary CSPC Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as "Jushi Bio") has recently initiated a randomized, open-label, multicenter Phase III clinical trial of SYS6010 combined with Enlangumab as first-line therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with negative driver genes and positive PD-L1 expression.
-
Product Overview
-
-
Biopharmaceuticals
-
-
Functional ingredients
-
-
Nutritional products
-
-
Biopharmaceuticals
The Company focused on cutting-edge biopharmaceutical areas such as antibody drugs, antibody-drug conjugates (ADC), and mRNA vaccines, with more than 20 projects currently under development. It has launched China's first mRNA vaccine, Duentai, the Class 1 new biological drug Enlonstobart injection, and Omalizumab for injection.
-
-
Functional ingredients
The products mainly include caffeine, acarbose, anhydrous glucose, etc. The caffeine products lead the world in production scale, and the production scale of acarbose raw materials ranks among the top in China, achieving industrialized production of acarbose products. It is currently one of the few domestic companies with an official drug approval number for acarbose APIs.
-
-
Nutritional products
The company has established a dietary nutrition product matrix with 8 major categories: Vitamin C, B vitamins, glucosamine, calcium, protein powder, coenzyme Q10, lutein, and melatonin, covering functional needs such as "immune support, bone health, improved sleep, digestive care, and antioxidation," as well as chronic disease health needs like "regulating the three highs" (blood pressure, blood sugar, and blood lipids).
